Amneal Pharmaceuticals (AMRX) EV to EBITDA (2018 - 2026)

Amneal Pharmaceuticals has reported EV to EBITDA for 9 years, with the latest figure at 42.26 in Q2 2026.

• On a quarterly basis, EV to EBITDA rose 85.66% year-over-year to 42.26 in Q2 2026; TTM through Jun 2026 was 12.08, a 79.35% increase from a year earlier, with the FY2025 full-year figure at 9.54, down 1.28% from the prior year.
• EV to EBITDA was 42.26 for Q2 2026 at Amneal Pharmaceuticals, up from 27.18 in the prior quarter.
• The five-year high for EV to EBITDA was 127.53 in Q4 2023, with the low at 174.1 in Q1 2024.
• Average EV to EBITDA over 5 years is 18.69, with a median of 24.54 recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: EV to EBITDA soared 661.84% in 2023, then plunged 2050.9% in 2024.
• Over 5 years, EV to EBITDA stood at 16.74 in 2022, then jumped by 661.84% to 127.53 in 2023, then plunged by 75.07% to 31.79 in 2024, then increased by 5.57% to 33.56 in 2025, then grew by 25.94% to 42.26 in 2026.
• The last three EV to EBITDA figures came in at 42.26 (Q2 2026), 27.18 (Q1 2026), and 33.56 (Q4 2025), per Business Quant data.